Tasman Therapeutics
Phase 3R-107 is the first and only oral extended-release ketamine tablet transforming Treatment Resistant Depression and other depressive disorders. Tasman Therapeutics is seeking strategic investors to advance this critical innovation. With support, we aim to bring hope to millions and capture a substantial share of this growing market.
About
R-107 is the first and only oral extended-release ketamine tablet transforming Treatment Resistant Depression and other depressive disorders. Tasman Therapeutics is seeking strategic investors to advance this critical innovation. With support, we aim to bring hope to millions and capture a substantial share of this growing market.
Funding History
2Total raised: $15M
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile